Delivering Pharmaceutical Innovations Domestically and Globally
Toward Realizing the JPMA's Vision for 2035Our activities are centered on the three pillars of Innovation, Access, and Trust.
Consistently produce innovations to benefit health spans and the economy
Bring innovative new drugs to the public more quickly to enhance health security
-
Consumer Consultation Review Committee
We have posted the “Medication Consultation Desk (for Healthcare Professionals).”
-
Drug Evaluation Committee
We have posted information on the “Symposium on Pediatric Drug Development: ‘Envisioning the Future of Pediatric Drug Development—Challenges in the New Era Brought About by Amendments to the Pharmaceutical and Medical Devices Act,’ to be held on March 17, 2026.”
Commit to ethical conduct and transparency to foster trust in the pharma industry
-
Announcement Patient Cooperation Committee
We have posted the “Disclosed Information for FY 2025 Payments” from the “Transparency Guideline for Relationships Between Corporate Activities and Patient Organizations.”
-
Announcement Code Compliance Committee
We have posted the “Disclosed Information for FY 2025 Payments” under the “Transparency Guideline for the Relation between Corporate Activities and Medical Institutions”
-
The latest issue of the JPMA Newsletter features a special interview on the “New Organization: Business Strategy Division,” along with coverage of various other activities of the JPMA.
-
Event Report: Updated August 18 Report on Participation in the “ICH Rio de Janeiro Meeting”
-
Scientific and Practical Requirements for Drug Candidate Substances for Companies ~Statement of TPP
-
JPMA's Vision for 2035" and "JPMA's Policy Proposals for 2025" released on Feb. 26, 2025
-
DATA BOOK 2026" is now available.
Updates
-
Announcement Patient Cooperation Committee
We have posted the “Disclosed Information for FY 2025 Payments” from the “Transparency Guideline for Relationships Between Corporate Activities and Patient Organizations.”
-
Announcement Code Compliance Committee
We have posted the “Disclosed Information for FY 2025 Payments” under the “Transparency Guideline for the Relation between Corporate Activities and Medical Institutions”
-
Public Affairs Committee Event Report
JPMA Presidents Press Conference" is now available.
-
ICH Project Event Report
We have posted a report on our participation in the “ICH Rio de Janeiro Meeting.”
-
Announcement
We have posted the “Materials from the JPMA President’s Press Conference Held on July 30.”
-
Public Affairs Committee
We have posted the report titled “The 19th Survey on Consumer Attitudes Toward Medicines and the Pharmaceutical Industry.”
-
Announcement Patient Cooperation Committee
We have posted the “Disclosed Information for FY 2025 Payments” from the “Transparency Guideline for Relationships Between Corporate Activities and Patient Organizations.”
-
Announcement Code Compliance Committee
We have posted the “Disclosed Information for FY 2025 Payments” under the “Transparency Guideline for the Relation between Corporate Activities and Medical Institutions”
-
Announcement
We have posted the “Materials from the JPMA President’s Press Conference Held on July 30.”
-
Announcement Public Affairs Committee
We have published the “JPMA Newsletter, July 2026 Issue No. 230.”
-
Announcement Quality & Technology Committee
We have posted information regarding the “FY2026 GMP Case Study Workshop.”
-
News Release
In Response to the Cabinet Decision on the “Basic Policy 2026”
-
Announcement Patient Cooperation Committee
We have posted the “Disclosed Information for FY 2025 Payments” from the “Transparency Guideline for Relationships Between Corporate Activities and Patient Organizations.”
-
Announcement Code Compliance Committee
We have posted the “Disclosed Information for FY 2025 Payments” under the “Transparency Guideline for the Relation between Corporate Activities and Medical Institutions”
-
Public Affairs Committee Event Report
JPMA Presidents Press Conference" is now available.
-
ICH Project Event Report
We have posted a report on our participation in the “ICH Rio de Janeiro Meeting.”
-
Public Affairs Committee
We have posted the report titled “The 19th Survey on Consumer Attitudes Toward Medicines and the Pharmaceutical Industry.”
-
Quality & Technology Committee Event Report
A report on the “FY 2026 (53rd) GMP Roundtable” has been posted.
-
Public Affairs Committee Event Report
JPMA Presidents Press Conference" is now available.
-
ICH Project Event Report
We have posted a report on our participation in the “ICH Rio de Janeiro Meeting.”
-
Quality & Technology Committee Event Report
A report on the “FY 2026 (53rd) GMP Roundtable” has been posted.
-
International Affairs Committee Event Report
We have posted an article titled “Side Event Report — 79th World Health Assembly (WHA79)”
-
Pharmaceutical Industrial Policy Committee Event Report
Participation Report: “Yakusai 2026—A Science Experience Event for Children and Adults Alike”
-
Pharmaceutical Industrial Policy Committee Event Report
Report on the JPMA Media Forum: “The Diverse Value Brought by Innovative Medicines—Using Pediatric Acute Lymphoblastic Leukemia (ALL) as a Case Study”
About JPMA
Under the JPMA Board of Directors, 12 committees composed of member companies and 6 specialized organizations, including the Office of Pharmaceutical Industry Research (OPIR) which functions as a think tank, carry out a wide range of initiatives. These activities aim to establish a robust drug discovery ecosystem for the development of innovative pharmaceuticals, ensure compliance with regulatory frameworks such as the Pharmaceuticals and Medical Devices Act, and build trust with key stakeholders.
Each committee and specialized body bring together a diverse pool of talent - from young professionals to experienced experts - working across organizational boundaries. Through mutual collaboration and constructive exchange, they advance pharmaceutical innovation, promote the appropriate use of medicines, enhance transparency in distribution, foster international cooperation, and formulate policy proposals. In addition, JPMA conducts various surveys and research projects to address industry-wide challenges. By working closely with government authorities, patient advocacy groups, and other relevant organizations, JPMA supports the sound and sustainable development of the pharmaceutical industry.
JPMA's Vision
Consistently produce innovations to benefit health spans and the economy
- Pharmaceutical innovations
- Leading-edge scientific technology
- Pharmaceutical manufacturing technology
- Domestic manufacturing infrastructure
- Making Japan a science and technology powerhouse
- Fostering highly skilled talent
- PPI/E
- Drug discovery that involves patients and the public
- Co-creation
- Drug discovery ecosystem
- Job creation
- Extending health spans
- Well being
- Pharma as a core industry
- Economic growth
Bring innovative new drugs to the public more quickly to enhance health security
- A social security system that gives patients swift access to “the latest treatments” and stable access to “global-standard treatments”
- Positive investment cycle
- Building an attractive domestic market
- Drug pricing that properly factors in the worth of innovation
- Health security for Japan
Commit to ethical conduct and transparency to foster trust in the pharma industry
- Sustainable Development Goal 3 (Ensure healthy lives and promote well-being for all at all ages)
- Overcome the social challenges raised by Japan’s aging population
- Ethical soundness, code of behavior, and transparency
- Boost public literacy in health and medicine
- Social significance of pharmaceuticals and the pharma industry
- Encourage the public and younger people to enter the pharma industry
- Climate change
- Environmental issues
Member Companies
The JPMA has 68 R&D-oriented JPMA member companies (as of June 1, 2026).
